Compare ONMD & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONMD | NEPH |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 60.0M |
| IPO Year | N/A | 2004 |
| Metric | ONMD | NEPH |
|---|---|---|
| Price | $1.55 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 2.6M | 74.6K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $494,000.00 | ★ $17,930,000.00 |
| Revenue This Year | N/A | $33.32 |
| Revenue Next Year | N/A | $12.27 |
| P/E Ratio | ★ N/A | $36.15 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $0.30 | $1.39 |
| 52 Week High | $4.22 | $6.42 |
| Indicator | ONMD | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 48.33 |
| Support Level | $1.46 | $4.83 |
| Resistance Level | $2.30 | $5.97 |
| Average True Range (ATR) | 0.23 | 0.63 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 20.41 | 28.93 |
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's technology has provens the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade, image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols, paving the way for Real World Evidence.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.